Rare immune-related adverse effect of pembrolizumab: pulmonary hypertension

Basit Öğe Kaydı
dc.contributor.authorAcar, Caner
dc.contributor.authorSahin, Gokhan
dc.contributor.authorYuksel, Haydar Cagatay
dc.contributor.authorKaraca, Burcak
dc.date.accessioned2024-08-31T07:50:58Z
dc.date.available2024-08-31T07:50:58Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractPembrolizumab is an immune checkpoint inhibitor that acts via PD-1 blockade. Recent studies have shown its effectiveness in treating various solid organ tumours. However, unlike cytotoxic chemotherapeutic agents, pembrolizumab may cause immune-related adverse effects. These immune-related adverse effects are generally mild, although patients who experience grade-three or higher side effects may require hospitalisation. In particular, cardiopulmonary side effects are associated with high mortality rates. We report the case of a 24-year-old female patient with alveolar soft part sarcoma accompanied by rare and difficult-to-treat pulmonary hypertension induced by pembrolizumab.en_US
dc.identifier.doi10.1080/1120009X.2024.2349858
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.pmid38717744en_US
dc.identifier.scopus2-s2.0-85192527266en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1080/1120009X.2024.2349858
dc.identifier.urihttps://hdl.handle.net/11454/105451
dc.identifier.wosWOS:001219031300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectImmunotherapyen_US
dc.subjectAdverse Drug Reactionen_US
dc.subjectImmune-Related Adverse Eventsen_US
dc.subjectPulmonary Arterial Hypertensionen_US
dc.titleRare immune-related adverse effect of pembrolizumab: pulmonary hypertensionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu